Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEXI-003
- Development stage
- Phase 1
- Lead developer
- NexImmune
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NEXI-003 is an autologous, antigen-specific T cell therapy developed by NexImmune for the treatment of relapsed or refractory human papillomavirus (HPV)-related cancers, particularly oropharyngeal and other head and neck squamous cell carcinomas. The product consists of patient-derived (autologous) CD3+ CD4- CD8+ T cells that are engineered to target multiple HPV tumor-associated antigens, including HPV16, HPV18, and survivin. These T cells are designed to recognize and attack cancer cells expressing these antigens while also promoting long-term immunologic memory for durable anti-tumor responses. NEXI-003 is currently in Phase 1 clinical trials[2][3][4][5].
- Other names
- autologous HPV16/HPV18/Survivin-specific CD8+ T cells
02
Targets
Sur1M2-HLA-A2 (Survivin-derived peptide–Major Histocompatibility Complex)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)Human papillomavirus type 18 E6 peptide-HLA-A*0201 complexHuman papillomavirus type 18 E7 peptide-HLA-A*0201 complex
Beyond the preview
Go deeper on NEXI-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEXI-003.